Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.
Sihuan Pharmaceutical Holdings Group Ltd. has announced a supplemental update regarding the transfer of shares in its subsidiary, Xuanzhu Biopharm. This transfer involves reducing the investment price per share for Series A Lead Investors by transferring 24,332,920 shares at no cost, thus lowering their effective investment cost. The valuation for this transfer was conducted using the market approach, specifically the listed companies comparison method, due to Xuanzhu Biopharm’s nature as an asset-light R&D enterprise without significant profits or revenue. This strategic move may impact the company’s financial positioning and investor relations, as it reflects adjustments in their valuation approach to accommodate the unique characteristics of their subsidiary.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. is a company in the pharmaceutical industry, focusing on research and development. It operates primarily through its subsidiaries, offering products and services related to biopharmaceuticals.
YTD Price Performance: 52.00%
Average Trading Volume: 165
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $719.5M
See more data about 0460 stock on TipRanks’ Stock Analysis page.
